IMPORTANCE People with epilepsy are at increased risk of mortality, but, to date, the cause-specific risks of all unnatural causes have not been reported.
P eople who receive a diagnosis of epilepsy are 2 to 3 times more likely than the rest of the population to die prematurely. The degree to which this relative risk is elevated varies by cause of death. 1, 2 Earlier research has focused on sudden unexpected death in epilepsy, with less attention paid to other causes. A recent call for action 3 identified the need to better understand cause-specific mortality risk, particularly for unnatural causes (ie, unintentional injury, suicide, homicide, and iatrogenesis), in people with epilepsy. Furthermore, the need for accurate identification of epilepsy and cause of death has been emphasized in epidemiologic studies. 4 Several secondary care-based observational studies have reported 2-to 5-fold increased risks of unnatural mortality. 1, 5, 6 Some studies examined the risk by type of unintentional injury, 5, 6 one reported the method of suicide in people with epilepsy, 7 but none comprehensively reported risks across the full range of suicide and unintentional injury or poisoning types. A previous study of suicide that used the US National Violent Death Reporting System reported that antiepileptic drugs (AEDs) were used in just 6% of intentional poisoning deaths in people with epilepsy. 7 This contrasts with a study of nonfatal self-poisoning in which AEDs were the most commonly used medication type (27%) in people with epilepsy. 8 We estimated the relative risks of the specific causes of unnatural mortality in people with epilepsy vs a matched comparison cohort without epilepsy. We used 2 linked primary care-mortality databases to accurately estimate risks of causespecific unnatural mortality. We also examined how frequently specific types of medication were involved in medication poisoning deaths.
Methods

Design, Setting, and Participants
We conducted 2 population-based cohort studies using data from the Clinical Practice Research Datalink (CPRD) and the Secure Anonymised Information Linkage (SAIL) Databank. The CPRD, a general practice database that covers approximately 7% of the population in the United Kingdom, contains anonymized patient-level data, including demographic characteristics, diagnoses, test results, and prescribed treatments. 9 We used the July 2015 data release, which included 13 979 404 patients whose data were deemed to be of acceptable research quality standards from 689 practices. This data set is considered representative of the age, sex, and ethnicity distributions of the UK population. 9 We identified epilepsy and comparison cohorts from a subset of practices whose anonymized patient data were linked to the following additional data sources: Office for National Statistics (ONS) mortality records, Index of Multiple Deprivation 2010, and Hospital Episode Statistics (HES). Those sources provide information on the cause of death (ONS), quintiles of deprivation based on patient postcodes (Index of Multiple Deprivation 2010), and inpatient hospitalizations (HES). 9 All of the linked practices were The general practice data set contains diagnostic, treatment, and test data from 360 general practices (76%) in Wales, including 4 052 388 patients. 12 Hospital admission diagnoses and discharge dates are detailed in the Patient Episode Database for Wales. The Annual District Death Extract provides ONS data on date and cause of death. 13 There was no overlap between the practices included in the CPRD cohorts and the practices included in the SAIL Databank cohorts because none of the Welsh practices in the CPRD were in the subset eligible for data linkage. The International League Against Epilepsy recommends the presence of both a diagnostic code for epilepsy and an AED treatment code for reliable ascertainment of epilepsy in epidemiologic studies.
14 We adopted this recommendation. Epilepsy diagnoses are recorded in the CPRD and the general practice data set using the Read code system, version 2. 15 Code lists were generated by searching for epilepsy-associated terms in the CPRD medical dictionary. This list was refined following discussion with a neurologist and in comparison with studies previously conducted using data from the CPRD 16, 17 and the SAIL Databank. 18 A list of AEDs licensed in the United Kingdom was produced by a pharmacist (H.C.G.) based on drugs listed in the British National Formulary (BNF 68) 19 and checked by another pharmacist (D.M.A.). We defined the epilepsy index date as the latest date at which a person had received both an epilepsy diagnostic code and an associated AED prescription. The AED prescription
Key Points
Question What is the risk and medication contribution to cause-specific unnatural mortality in people with epilepsy?
Findings In this population-based cohort study, more than 50 000 people with epilepsy and 1 million matched individuals without epilepsy were identified in 2 data sets from the general populations of England and Wales. People with epilepsy had a 3-fold increased risk of any unnatural mortality and a 5-fold increased risk of unintentional medication poisoning; psychotropic and opioid, but not antiepileptic, drugs were most commonly used in poisoning.
Meaning Clinicians should provide advice on unintentional injury and poisoning and suicide prevention and consider the toxicity of concomitant medication when prescribing drugs for people with epilepsy.
could have been issued in the month before or up to 6 months after the date of the diagnostic code. We required the index date to be within the study periods, which we defined based on corresponding linkage availability as January 1, 1998, to March 31, 2014 , for the CPRD and January 1, 2001, to December 31, 2014, for the SAIL Databank. Follow-up began on the index date, which occurred after registration of the patient in a practice. Separately for the CPRD and the SAIL Databank, we matched people with epilepsy with up to 20 individuals who had never received a diagnostic code for epilepsy and were alive on the date that follow-up began (eAppendix in the Supplement). We matched these comparison cohorts to their respective epilepsy cohorts on sex, year of birth (within 2 years), and general practice (Figure 1) . Members of the comparison cohorts were followed up from the same day as the individuals they were matched to in the epilepsy cohort.
We followed the epilepsy and comparison cohorts until the earliest date of death, transfer out of the practice, end of data collection from the practice, or study end. It was possible using the SAIL Databank to follow the progress of patients who transferred to other practices.
This study is reported in accordance with the Reporting of Studies Conducted Using Observational RoutinelyCollected Health Data (RECORD) statement. 20 We identified diagnoses and treatments using general practice data. We used published Read code lists to identify patients who had received a diagnosis of a range of mental illnesses. 21, 22 Our code lists for migraine, neuropathic pain, and substance misuse were verified by 2 general physicians and are available along with the epilepsy and AED codes at the ClinicalCodes.org website. 23 Hospital discharge diagnoses were identified using the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) coding system. 24 
Cause-Specific Mortality Outcomes
We determined the cause of death from the ONS-recorded underlying cause of death, as coded by the ICD-10 codes as fol- . We included events of undetermined intent in suicide estimates as per convention in the United Kingdom because most of these deaths were likely due to suicide. 25 We identified the specific types of medication involved in poisoning deaths according to the presence of ICD-10 codes T36 through T50 in the supplementary causes of death fields (eTable in the Supplement).
Statistical Analysis
We applied a common protocol to conduct separate analyses of data from the 2 databases using Stata, version 13 (StataCorp). Baseline characteristics were reported as numerical and percentage frequencies, medians, or means and compared using unpaired, 2-tailed t tests, Mann-Whitney tests, or χ 2 tests, as appropriate. We examined the proportion of individuals per cohort with mental health diagnoses, neuropathic pain, or migraine before or after cohort entry. We calculated mortality rates by dividing the number of events by the sum of person-years at risk. We accounted for the matched design by fitting stratified Cox proportional hazards models to estimate unadjusted and adjusted hazard ratios (HRs) for specific causes of death. Proportionality assumptions were examined using a test for Schoenfeld residuals and visually by graphical inspection. Adjustments were made for area-level deprivation because people with epilepsy are known to reside in more deprived areas than those without epilepsy, 18 which may independently increase the risk of death. Deprivation was recorded by quintiles using the Index of Multiple Deprivation 2010 in the CPRD and the Welsh Index of Multiple Deprivation in the SAIL Databank. In the event the level of deprivation was missing, individuals were assigned to a category called unknown.
We conducted a meta-analysis of the HRs estimated from each data set using DerSimonian and Laird random-effects models implemented via the metan command in Stata. 26 In addition, we restricted the cohorts to the incident epilepsy and comparison cohorts and estimated risks for the 4 main subgroups (all-cause mortality, unnatural death, unintentional injury, or suicide). The purpose of this sensitivity analysis was to explore whether there was evidence of a survival bias in using the prevalent cohort for our primary analysis. We also generated Kaplan-Meier survival estimates for all unnatural deaths separately for the 2 data sets, accounting for competing risks. The frequency of involvement of each medication type in poisoning deaths was pooled across the CPRD and the SAIL Databank and reported as percentages of all poisoning deaths for the prevalent cohorts. The analysis was conducted from January 5, 2016, to November 16, 2017.
Results
We matched 44 678 people with epilepsy to 891 429 persons without epilepsy in the CPRD, and 14 051 people with epilepsy to 279 365 individuals without epilepsy in the SAIL Databank ( Figure 1 ). The baseline demographic and clinical characteristics are described in Event counts and mortality rates for each unnatural cause of death are presented separately for the 2 data sets in Table 2 . The HRs of the meta-analysis for cause-specific unnatural mortality adjusted for area-level deprivation are shown in Figure 2 . These estimates were similar to the unadjusted estimates. Compared with persons without the condition, people with epilepsy were at an increased risk of unnatural mortality (deprivation-adjusted HR, 2.77; 95% CI, 2.43-3.16). We observed this elevated risk for both unintentional death (deprivationadjusted HR, 2.97; 95% CI, 2.54-3.48), which represented the majority of unnatural deaths ( Sensitivity analyses identified 14 057 people with incident epilepsy in the CPRD and 263 610 people without in the comparison cohort and 7274 people with incident epilepsy in the SAIL Databank and 144 287 people without in the comparison cohort. The HRs estimated from a meta-analysis of the incident cohorts were similar to those estimated from the prevalent cohorts (Figure 3) . The cause-specific survival rates for unnatural death after 5 years in the CPRD were 99.7% (95% CI, 99.5%-99.8%) for the epilepsy cohort and 99.8% (95% CI, 99.8%-99.8%) for the comparison cohort, and those rates for the SAIL Databank data were 99.5% (95% CI, 99.3%-99.7%) for the epilepsy cohort and 99.8% (95% CI, 99.8%-99.8%) for the comparison cohort (eFigures 1 and 2 in the Supplement).
Discussion
In 2 primary care-and mortality-linked databases, people with epilepsy had an increased risk of all types of unnatural mortality compared with those without epilepsy. In people with epilepsy and in a matched comparison cohort, psychotropic medication and opioids were the medicine groups most commonly used in poisoning deaths, with AEDs reported much less frequently. To our knowledge, this is the first study to comprehensively examine cause-specific unnatural mortality risks, including both unintentional and intentional medication poisoning separately, in people with epilepsy.
Our relative estimates for all unnatural deaths, unintentional deaths, and suicides are in the same direction, but they are generally lower than those recorded in studies conducted using secondary-care records. episodes with some outpatient coverage. 5,6 Therefore, it is possible that only individuals with more severe epilepsy were included. By using 2 primary-care data sets, we showed that increased risks extend to people with epilepsy in the community. Only 1 other study 6 has estimated the specific risk of unintentional poisoning; the reported odds ratio of 5.1 (95% CI, 3.9-6.5) was similar to our meta-analyzed HR in the present study. The reasons for the increased risk of unintended death may include the direct consequences of seizures 3 or may be unassociated with epilepsy. The mental illness comorbidities associated with epilepsy are also associated with increased risk of unintentional injury and poisoning 28 and suicide. 29 Indeed, we detected greater proportions of people in the epilepsy cohort than in the comparison cohort who had received diagnoses involving mental health at baseline and during follow-up. There have been suggestions that suicidality and epilepsy share common neurological pathways, 30 which could explain the increased risk of suicide. Clinicians should explore any symptoms of mental illness in people with epilepsy and ask about suicidal thoughts. In addition, the psychosocial impact and stigma surrounding epilepsy may contribute to the increased risk of unnatural death. 31 It is possible that the stigma or presence of comorbid mental illness explains much of the 3-fold increase in homicide risk that we observed, an estimate consistent with that reported from a Swedish registry study (adjusted odds ratio, 2.8; 95% CI, 1.6-4.8).
5
The increased risk of poisoning death identified in the present study might be attributable to the accessibility of medication in people with epilepsy, both AEDs and medication prescribed to treat comorbidities. The ease of access to a means to take one's own life strongly influences suicide risk. 32 However, AEDs were relatively infrequently recorded as being used in unintentional or intentional poisoning deaths in people with epilepsy. Our estimate that AEDs were used in onetenth of poisonings is similar to that shown by Tian et al, 7 who
reported AED involvement in 6% of suicides in people with epilepsy. Many of the AEDs used may have a lower relative toxicity than psychotropic drugs and opioids. This may have changed over time owing to a reduction in the use of phenobarbital, 33 which historically contributed to more than half of AED poisonings. 34, 35 However, AEDs are frequently involved in nonfatal self-harm. 8 Ongoing vigilance is required to monitor nonfatal self-harm and poisoning deaths as trends in AED prescribing change. The ONS records indicate increasing involvement of gabapentin and pregabalin in poisoning deaths. 36 This has been largely attributed to the diversion of pregabalin and gabapentin for recreational use. 37 Because these AEDs are commonly used for treating conditions other than epilepsy, their involvement could extend beyond people with epilepsy.
Strengths and Limitations
The present study meets the International League Against Epilepsy recommendations for defining epilepsy 14 and classifying mortality by cause 4 in epidemiologic studies. A major strength of our investigation is that we examined 2 large, linked, and nationally representative primary-care data sets. Our outcomes were identified using ONS mortality statistics, which is the most accurate method of ascertaining cause of death in the United Kingdom. These primary-care data sets encompassed the whole spectrum of epilepsy, without restriction to more severe cases, which occurs in hospital-based cohorts. We applied a common study protocol across both data sets to enable a meta-analysis of the relative risks even when observed event counts were small. The increased risk of intentional selfpoisoning that was observed in the meta-analysis would not have been detected using only the SAIL Databank. In addition, we verified our main findings by comparison with an incident epilepsy cohort. We are aware of the potential limitations common to research using routinely collected data to investigate outcomes such as suicide. First, the data sets are not generated primarily for the purpose of conducting research, and residual confounding may therefore be present. Second, some suicides may have been misclassified. We accounted for this by including unnatural deaths of undetermined intent in our suicide definition. However, coroners in England and Wales have in recent years more frequently used narrative verdicts to describe likely suicides, rather than assigning a specific verdict. 38 Some of the estimates in the present meta-analysis were of low precision owing to low event counts for the rarest cause-specific mortality outcomes. For this reason, we could not estimate risks for specific subgroups of unnatural death in the incident epilepsy cohort. We were unable to report the medication involvement for each data set independently without compromising
anonymity. In addition, we could not subdivide the medications beyond that deducible from ICD-10 "T" codes.
Conclusions
In summary, the results of the present study showed that people with epilepsy have increased risks for most specific causes of unnatural death, including unintentional and intentional poisoning by medication. Further research is needed to identify suitable measures to mitigate these risks. Meanwhile, clinicians should be aware of the increased unnatural mortality risks and should carefully monitor patients accordingly. Antiepileptic drugs seemingly played a minor role in poisoning deaths, with psychotropic drugs and opioids more often involved. Therefore, when prescribing drugs for people with epilepsy, the potential for poisoning and associated relative toxicity of concomitantly prescribed medication should be considered in light of the increased risk of fatal poisoning in this population. 
eAppendix. Explanation of the Matching Process Applied to Delineate the Matched-Cohort Study
Separately in the CPRD and the SAIL Databank, people with epilepsy were matched to up to 20 individuals who had never received a diagnostic code for epilepsy and were alive on the date that follow-up began. They were matched on gender, year of birth (+/-2 years) and registered general practice; and followed up from the same day as the corresponding individual in the epilepsy cohort. We employed an algorithm that used nearest-neighbor matching. Individuals were ineligible for inclusion in the comparison cohort if they ever had a diagnostic code for epilepsy. In both the epilepsy and comparison cohorts, at least one day of follow-up after the entry date was required. The matching ratio of up to 20:1 was used to improve statistical power to detect rare outcomes, in line with evidence reported by Hennessy et al. that there are benefits to increasing the matching ratio for case-control studies above 5:1 when the exposure prevalence is low among control subjects. (1) Therefore, an increased matching ratio will be beneficial for the matched cohort design when incidence is very low in the comparison cohort. It enables more precise estimation of relative risks for exceptionally rare specific causes of death such as homicide. Whilst this matching ratio was desired, in practice it was not possible to match all individuals with epilepsy to 20 people. This was because there were not enough individuals who were the same gender, had the same year of birth (+/-2 years), were registered in the same general practice and who had never had a diagnosis of epilepsy. Each individual was matched to as many individuals as possible who satisfied the matching criteria. In the CPRD there was a median of 
eTable. ICD-10 Codes Used to Classify Medication Taken in Fatal Poisonings
Medication Group Codes Psychotropic medication T40.5, T40.7, T40.8, T40.9, T42.4, T43.0-9, T50.5 Opioid T40.0-4, T40.6 Non-opioid T39 Antiepileptic Drugs T42.0-3, T42.5-7 Other T36-38,T41,T42.8,T44-49,T50.0-4, T50.6-9 ICD-10 codes listed in supplementary cause of death fields in the ONS mortality record
